University of Tasmania
Browse

File(s) under permanent embargo

Novel oral anticoagulants in atrial fibrillation

journal contribution
posted on 2023-05-22, 05:24 authored by Luke BereznickiLuke Bereznicki

You are reviewing the medication profile of Mrs HH, a 76-year-old woman with a history of atrial fibrillation and hypertension. Her renal and hepatic function are normal. She is currently taking enalapril 20 mg/ hydrochlorothiazide 6 mg once daily, metoprolol 50 mg twice daily and aspirin 100 mg once daily. You notice she has risk factors for stroke (age and hypertension), no apparent risk factors for bleeding apart from her age and use of aspirin (hypertension is we/I-controlled), so you decide to recommend her GP consider prescribing an anticoagulant. You are aware that, in addition to warfarin, several new anticoagulant medicines are available. Which anticoagulant would you recommend?

After reading this article, pharmacists should be able to:

  • Describe the mechanism of action of novel anticoagulants (NOACs)
  • Outline and compare the characteristics of NOACs
  • Discuss how NOACs differ with respect to effectiveness, precautions, contraindications and adverse effect profies.

History

Publication title

Australian Pharmacist

Volume

33

Issue

10

Pagination

62-66

ISSN

0728-4632

Department/School

School of Pharmacy and Pharmacology

Publisher

Pharmaceutical Society of Australia

Place of publication

Deakin West, ACT.

Rights statement

Copyright 2014 Pharmaceutical Society of Australia Ltd.

Repository Status

  • Restricted

Socio-economic Objectives

Other health not elsewhere classified

Usage metrics

    University Of Tasmania

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC